PXIIX | VIVIX | PXIIX / VIVIX | |
Total Expense Ratio | 0.95 | 0.04 | 2,375% |
Annual Report Gross Expense Ratio | 1.11 | 0.04 | 2,775% |
Fund Existence | 18 years | 27 years | - |
Gain YTD | 11.948 | 7.866 | 152% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 100000 | 5000000 | 2% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 137M | 203B | 0% |
Annual Yield % from dividends | 2.83 | 2.11 | 134% |
Returns for 1 year | 11.56 | 7.74 | 149% |
Returns for 3 years | 25.04 | 36.61 | 68% |
Returns for 5 years | 9.10 | 70.16 | 13% |
Returns for 10 years | 57.69 | 131.61 | 44% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SBHIX | 23.44 | 0.21 | +0.90% |
Saratoga Health & Biotechnology I | |||
ETLNX | 15.55 | N/A | N/A |
Eventide Large Cap Focus N | |||
EKBCX | 14.76 | -0.02 | -0.14% |
Allspring Diversified Cap Bldr C | |||
GCVAX | 25.09 | -0.04 | -0.16% |
Goldman Sachs Large Cp Val Insghts A | |||
OTCNX | 80.12 | -0.18 | -0.22% |
Invesco Discovery Large Cap R |